Dave Alderman, Molekule Consulting
Dave Alderman, President, Molekule Consulting
David Alderman is President of Molekule Consulting (“Molekule”), a global competitive intelligence and management consultancy headquartered in Miami, Florida. Molekule partners with pharmaceutical, biotechnology and medical device companies providing evidence-based solutions and actionable strategic and tactical insights. Aligning intelligence outcomes and focusing results thereby enabling our client partners — blue chip pharmaceutical and biotechnology players — to win in the highly dynamic and competitive biopharmaceutical universe, Molekule supports seminal biopharmaceutical business objectives. We leverage a continuum of tactical and strategic decisions for pharmaceutical, biotechnology and medical device clients via informed, pragmatic and meaningful competitive intelligence & consulting solutions.
David’s core strength is in partnering with biopharmaceutical clients to develop actionable strategies and critical insights driving business development, sustainable growth, overall strategy and transformational gains for Molekule’s client partners.
David is recognized as a Therapy Area Leader (“TAL”) with an in-depth understanding of multiple disease states, current and future market players, and developmental pipeline compounds in multiple markets and therapeutic areas.
David’s efforts have helped pharmaceutical and biotech companies grow revenues, profits and market share in highly competitive and emerging markets, resulting in a high level of client satisfaction and retention.
Shannon Altimari, TESARO
Shannon Altimari, Head of Corporate Affairs, International, TESARO (Invited)
Dr. Rachid Benhamza, Helsinn Healthcare S.A.
Dr. Rachid Benhamza, Director Product Management, Commercial Operations, Helsinn Healthcare S.A.
Dr. Rachid Benhamza is Head of Corporate Product Management & Competitive Intelligence, Commercial Operations, at Helsinn Healthcare Switzerland.
In his career Rachid Benhamza has the opportunity to develop a wide experience in the Pharmaceutical Industry covering basic research and teaching at the University of Geneva, manufacturing of APIs in a couple of Swiss chemical plants, international sales management, licensing and business development where he spent over 10 years working on a worldwide basis, to his current position where he manage with his coworkers commercial teams responsible for the preparation and launch of new drugs. His current responsibility covers also the maintenance of an active Intelligence in the markets and in the therapeutical areas of interest for the company.
Among his activities within several associations, Rachid Benhamza is currently a board member of the Swiss Healthcare Licensing Group (previously Swiss Pharma Licensing Group, www.swisshlg.com), an association of 150 Executives working in business development and licensing, he co-founded 12 years ago, with other colleagues in the Swiss Pharma industry. He acted as vice-president and then president of this association until 2012.
Almudena Berzosa, Johnson & Johnson Family of Companies
Almudena Berzosa, General Market Intelligence Lead, CM/SM Center of Excellence, Global Enterprise Procurement, Johnson & Johnson Family of Companies (Invited)
Almudena Berzosa is currently working at Johnson & Johnson, leading general Market and Competitive Intelligence for Global Procurement Enterprise. Her scope includes the 3 sectors of the J&J family of companies: Pharma, Medical Devices and Consumer. Previously she worked for Syngenta Crop Protection where she was responsible for Indirect Market Intelligence in Global Sourcing.
Almudena, is a certified CI practitioner and holds an MBA in business administrations, an MSc in Psychology and an MSc in Pharma Addictions. She is a passionate about driving functional excellence and providing actionable insights to guide business decisions as well as finding collaboration opportunities across departments and ways to exchange insights and leverage on the corporate intelligence.
Almudena is also an active member of a number of nonprofit organizations related with Science and People Development.
Sheila Campos, Bayer
Sheila Campos, Vice President Global Commercial Insights & Analytics, Bayer (Invited)
Sheila Campos is the Vice President of Global Commercial Insights & Analytics at Bayer Pharmaceuticals AG with responsibility for the delivery of global insights, competitive intelligence, forecasting and advanced analytics in Bayer’s key global markets. Prior to joining Bayer in 2014, Sheila had an 18 year career in roles of increasing responsibility within the pharmaceutical industry at Amgen and Pfizer Inc.
She started her career in consumer packaged goods in market research and new products marketing roles at Mars Inc. Sheila has an MBA in Marketing from UCLA and also serves on the Board of the European Pharmaceutical Market Research Association.
Rob Chisholm, Kyowa Kirin International
Rob Chisholm, VP Commercial Operations, Kyowa Kirin International
Daniel Cho, Philips Healthcare
Daniel Cho, Director Marketing, Global Pricing & Competitive Portfolio Analytics, Philips Healthcare
Daniel is current the head of Global Pricing and Competitive Portfolio Analytics for Philips PCMS a 2.5B Euro branch within the Philips Healthcare business. Daniel started his career as a Management Consultant under PriceWaterhouse Sydney, then move on to have multiple Sales and APAC Sales Development positions before landing into a Global product manager position in Germany. While as the product manager position, Daniel had created the most profitable product Intellivue X2 for the Patient Monitoring business based on his extended knowledge of customer insight which drive a strong differential value proposition for the customers and for Philips. Daniel then take on the role of heading both Market Intelligence as well as Global New Product Introduction. Within the role, Daniel had development a strong knowledge management platform within Philips PCMS which now just pasted the 9 year mark and serving more than 2,000 individuals on a daily basis.
Daniel most recently took on a Global Pricing role, which has direct impact on the top and bottom line of the business. Major contribution for his team is to have successfully reversed the global price erosion for the most recent 3 quarters of business across all businesses. This bought very strong bottom line improvement while business still grew strong at high single digit.
Daniel had a passion for Competitive Intelligence and had been contributing to the global CI network within Philips PCMS. Recently he also took the role to head that function and making sure that Philips sales team getting the most impactful and updated competitive information, and make available multiple tactical tools for sales people to win the next deal. This unique use of CI information on a daily and per deal level brought along strong growth in market share despite operating in a very competitive and price driven environment.
Overall Daniel is most known for his knowledge in topics of Market Intelligence, Competitive Intelligence, Knowledge Management, Pricing and Profitability Improvement, Visual Analytics, Innovation and Value Propositions. Daniel was a keynote speaker in various global conferences and working with large global organizations as panel member and advisor.
Jennifer Cummins, Vifor Pharma
Jennifer Cummins, Director of Market Research & Competitive Insights, Vifor Pharma
Jennifer Cummins has been working in the life science sector since 2004 with positions in the UK Department of Trade & Industry, McKinsey & Co, and Pharmaceutical companies including Nycomed, Takeda and Cubist. Her current position is as the Director for Competitive Insights & Market Research at Vifor Pharma, headquartered in Zurich, Switzerland.
Orientina Di Giovanni, Zambon
Orientina Di Giovanni, Head of Global Marketing – Established Products Business Unit, Zambon
Orientina is the Head of Corporate Marketing at Zambon. She joined the company in 2006 as Strategic Planning Director and today she is responsible for marketing strategies of Primary Care and OTC global brands. Since 2013 Orientina is also leading the new CNS Franchise development, including Safinamide Go To Market Strategy – a new product for Parkinson Disease that was in-licensed in 2012 from Newron Pharmaceuticals with worldwide licensing rights (with the exception of Japan and the Far East).
Before joining Zambon, Orientina worked in several industries including Strategic Consulting, Publishing and Communication. She graduated in Economics and Social Sciences at Bocconi University in Milan. She is a proud (and distressed) mother of a girl and boy.
Dennis Engelke, Jazz Pharmaceuticals
Dennis Engelke, Director, Business Analysis & Insight, Jazz Pharmaceuticals
Since joining Jazz Pharmaceuticals in 2015, Dennis has been working in the International Portfolio Planning team responsible for the analysis and monitoring of the current Haematology and Oncology business by providing commercial insights which meaningfully improve brand strategies across the International region. In addition, he is assessing development assets or acquisition targets, contributing towards the final Go/No-Go decision. He is working in close collaboration with the commercial, medical, and business development leadership teams ensuring identification of insights, transfer of best practice and a holistic assessment of new product targets.
Dennis has 10 years of hands-on experience in the innovative and generic pharmaceutical industry and held previously global strategic marketing, business development and business intelligence positions for Specialty Pharmaceuticals at Actelion Pharmaceuticals and Fresenius Kabi.
He holds a Master degree in Business and Economics from the Universities of Hamburg (Germany) and Uppsala (Sweden).
Jacob Falck Hansen, Ph.D., Novo Nordisk A/S
Jacob Falck Hansen, Ph.D., Vice President Competitive Intelligence Diabetes, Novo Nordisk A/S
Jacob heads the unit in Novo Nordisk responsible for CI within Diabetes and Obesity. He has been with Novo Nordisk since 2007 and worked in various business development and strategic planning roles and before joining the competitive intelligence unit in 2011. Prior to joining Novo Nordisk, he worked at the University of Cambridge, UK, and the Danish Cancer Society, and he has a Ph.D. in Molecular Biology from University of Copenhagen.
Vivian Ho, Elanco
Vivian Ho, Portfolio Strategy Manager, Elanco
Vivian is a Portfolio Strategy Manager at Elanco (Animal Health division of Eli Lilly). She comes from a multi-cultural and multi-discipline background, having lived and worked in Asia, Oceania, and Europe. Her formal education is law and business, and she has worked in professional services, business development, general management, and portfolio strategy roles in different companies and industries. Involving and building strong trust with her colleagues is a key component of her career, and this has enabled her teams to make a bigger contribution than the sum of individual efforts.
Philippe HODDÉ, Sanofi Pasteur
Philippe HODDÉ, Senior Director Competitive Intelligence, Sanofi Pasteur (Invited)
Philippe HODDÉ is Senior Director of Competitive Intelligence in Sanofi Pasteur. During 20 years, he held various positions as marketing head in food industry, consulting in industrial risks management, and head of masters degrees in a Business School. He is engineer, master in administration, master in training engineering, and holds a Ph.D in management sciences, focused on Competitive intelligence. This transversal experience and background allow him having a transversal understanding of strategic issues, through adapted methodologies, tools and concepts. Philippe actively contributes to the formulation of the strategic intelligence academic corpus by teaching how strategy and competitive intelligence are closely linked, in various engineering schools and masters.
Philippe joined the Sanofi Pasteur’s Corporate Strategic Intelligence team in 2006. As CSI senior analyst, Philippe covers emerging markets field of analysis, and is actively involved in the evolution of the team, and the improvement of its skills and methods.
Bruno Larvol, The Larvol Group
Bruno Larvol, President, The Larvol Group
Bruno Larvol founded The Larvol Group in 2004. The company offers innovative intelligence solutions to 9 of the top 10 pharmaceutical companies. Over the past 18 years, Mr. Larvol has built a successful track record in the pharmaceutical field with industry leaders such as IBM Healthcare Consulting (The Wilkerson Group), Sandoz (Novartis), and Lehman Brothers. He holds an MBA with distinction from the Kellogg School of Management, an MS in biotechnology from Northwestern University, and a BA summa cum laude from Sorbonne University, Paris.
Mr. Larvol serves on the Biotechnology Advisory Board of the Kellogg Graduate School of Management.
Antonio Leao, Lilly Portugal, Produtos Farmacêuticos, Lda.
Antonio Leao, Country Manager, Lilly Portugal, Produtos Farmacêuticos, Lda. (Invited)
Marc Limacher, INOVIS
Marc Limacher, MBA, Founder and CEO, INOVIS
Marc Limacher started the company in 1992 as a boutique primary CI specialty firm focusing mostly on the IT and life sciences industries.
As a 28-year veteran in the CI and counter-intelligence industry, he has grown INOVIS into a global leader in primary intelligence & strategic consulting services, counting a select group of global Blue Chip companies as loyal clients. The introduction of an expert regulatory intelligence practice as well as the ProACT scenario planning software tool are unique in the industry.
Prior to INOVIS, Marc was Director of Market Intelligence at a leading West Coast institutional investment firm for five years, providing primary intelligence on small-/medium-/large-cap equities via a global employee network of 65 investigative journalists. He also delivers custom CI seminars and is a frequent lecturer on CI and counter-intelligence topics at companies and to academia.
Marc is fluent in 5 languages and enjoys the proximity to the ski slopes from the Lucerne office, the proximity to the Pacific waves from the Palo Alto office, and the proximity to NYC from the Princeton NJ office.
Lubos Marek, Alexion Pharma GmbH (Invited)
Lubos Marek, Head of Global Marketing Operations & Launch Excellence, Alexion Pharma GmbH (Invited)
Tony Nagle, Dig Worldwide
Tony Nagle, Co-founder, Dig Worldwide
Tony started working in the pharma industry 27 years ago for GSK, Roche and then for Bayer. His last role within the Pharma industry was as Vice President of Marketing and Commercial Operations for Bayer’s Biological Products Division. Therapy areas where Tony has acquired a detailed knowledge are; Diabetes, Cardiology /Dyslipidaemia, Haemophilia, Anti-infectives, Rheumatology, Ophthalmology, CNS, Women’s Health, Urology, Respiratory and specific areas of Oncology. For the past nine years Tony has worked in the professional services sector first leading Fuld & Company, an established competitive intelligence agency in Europe, and then two years ago co-founding with Beth Elliott, Dig Worldwide, a competitive intelligence consultancy focused on primary intelligence gathering. Historic career highlights have included:
• Twelve years of pharmaceutical general management and operations experience in running affiliate companies in New Zealand, PR China, USA and Denmark
• Global marketing and product development
• Concluding a number of news making licensing deals to enhance R&D pipelines
• Successful transitioning from an industry focused career to the professional service sector by running a specialist agency for nearly 7 years
Today with Dig Worldwide Tony is focused on
• Asking the right questions , primary intelligence gathering and engaging with right sources – digging deep
• Primary research analysis to assist Dig Worldwide clients to understand the external competitive environment- digging deeper
• Game Storming design and moderation
Tony obtained his first degree in Microbiology and Virology from Warwick University and then completed a few years later a post graduate degree in International Marketing. He now lives and works in the South East of England with his wife Yolanda and two eleven year olds , Calum and Clara.
Massimo Orlando, Alfasigma
Massimo Orlando, International Business Support Manager, Alfasigma (Invited)
Dr. Massimo Orlando is an experienced Pharmaceutical Manager from 16 years involved in Business Excellence through different roles: Salesman, Marketing Manager and Competitive Intelligence. His objective is to make Strategic Marketing and Competitive Intelligence a lighthouse for Company’s Business navigation.
Biology Researcher first, he started in Pharma as a Medical Rep in UCB in 2000, reaching Italian sales top performances, especially in direct sales to retail Pharmacies.
In 2003 he was recruited by a top Italian Pharma Company, sigma-tau spa (today Alfasigma, 1Bn € turnover, 2.800 employers ww), assuming growing leadership roles in Marketing Management and Competitive Intelligence.
He is now responsible for Strategic Marketing, Market Analytics and Competitive Intelligence for all International Company Activities (EMEA, APAC, LA), managing multiple sources of information and data and with significant roles in Strategic Planning and new, proprietary or licensed, product opportunities evaluation.
In performing his work, Massimo capitalizes on his formation in different fields like TV communication and journalism or teaching professional and enthusiastically welcomes the always new challenges that arise.
Sara Panigone, Chiesi Farmaceutici S.p.A.
Sara Panigone, Competitive Intelligence Group Manager, Chiesi Farmaceutici S.p.A.
Sara Panigone started working in Chiesi Farmaceutici headquarter in 2007 as Scientific Adviser in the Department of Scientific Affairs within Corporate Marketing with tasks spanning from scientific support to Corporate products to new licensing opportunities evaluation. In early 2009 she became Scientific Intelligence Adviser until, in January 2011, she assumed the role of Competitive Intelligence Manager within the CI Unit in Corporate Marketing. The CI Unit currently works in support to several Company functions, including Board of Directors, Marketing and R&D, through scenario and competitors analyses, war games and alerting systems.
She graduated in Medical Biotechnology in 2004 at the University of Milan; between 2004 and 2007 she obtained a PhD in Biotechnology Applied to Medical Sciences at the University of Milan in collaboration with Stanford University, where she worked as visiting researcher for 18 months.
Daniel Pascheles, Molekule Consulting
Dr. Daniel Pascheles, CEO, Molekule Consulting
Daniel joined Molekule Consulting in early 2017 as Chief Operating Officer and has over 20 years of experience in building world-class global competitive intelligence. As manager of large CI teams, Daniel oversaw and led during his successful career in the biopharmaceutical industry hundreds of primary CI projects, competitive simulations and strategic planning sessions. Prior to joining Molekule Consulting, Daniel was Vice President and Head of Global Competitive Intelligence at Merck & Co /MSD for the last 12 years. Before that he worked for Aventis and its predecessor company (Hoechst Marion Roussel, Marion Merrell Dow) for 14 years in various positions such as Global Head of CI, European Head of Sales and Marketing Administration, European Head of Strategic Planning and General Manager Switzerland.
Alice Pietralunga, Chiesi Farmaceutici S.p.A.
Alice Pietralunga, Junior Competitive Intelligence Advisor, Chiesi Farmaceutici S.p.A.
Alice Pietralunga has been working in Chiesi Farmaceutici headquarter since 2012. She started as Junior Business Analyst within Strategic Planning Department by collaborating in an internal project focused on scouting and evaluating new opportunity in Rare Disease & Orphan Drug area. She joined Corporate Marketing in 2013 as Junior Global Competitive Intelligence Advisor for Special Care and Rare Disease therapeutic areas within the Global Competitive Intelligence Department where Alice still works. Her main activities are focused on scenario and competitors analysis as well as ordinary reporting and alerting activities in support of several Company functions, both at Corporate and Affiliate level.
Alice graduated in Pharmaceutical Chemistry in 2012 at the University of Parma by focusing her dissertation research on Analytical Chemistry
Dr. Pablo Prados, Sanofi
Dr. Pablo Prados, Senior Director, Integrated Care, Global Biologics Division, Sanofi
Pablo Prados is Senior Director, Integrated Care Center of Excellence, Global Divisions & Strategic Development, in Sanofi.
Prior to this position, he was head of the Global Product Patrimony Management function in Global Operations, and the Global Competitive Intelligence function in R&D.
Pablo has worked in Japan for over 10 years in the Pharmaceutical industry, holding positions in both R&D and Pharmaceutical Operations, such as Regulatory Affairs Manager with Schering AG, Strategic Planning Director with Nippon Roche, New Products & Opportunities Head with Aventis Japan, and Business Analysis Head with sanofi-aventis Japan, before moving to France in 2007.
Pablo was born in Madrid and is a French and Spanish citizen. Pablo holds PhDs in Pharmaceutical Sciences from the University of Tokyo and the University Complutense of Madrid, and he received his EMBA from Temple University, PA, US.
Elsa Primpidou, Prescient Healthcare Group
Elsa Primpidou, Ph.D, Head of Business Development, Europe, Prescient Healthcare Group
Michael Pröschel, Vifor Pharma
Michael Pröschel, Head of Northern Europe and General Manager, Vifor Pharma
Michael is the Head of the Northern European Region and General Manager Germany for Vifor Pharma (www.viforpharma.com). He has over 20 years of hands-on experience in general management, sales, marketing and clinical research in the pharmaceutical industry, both in international and national functions – including hospital and retail brands. He is and has been a member of various strategic working groups within the companies he has been working for.
Nicolas PY, Debiopharm S.A.
Nicolas PY, Director, Head of Market Intelligence & Group Strategic Committee Facilitator, Debiopharm S.A.
Nicolas PY has 12 years of experience in Competitive Intelligence in various settings.
He started his career as an analyst at a consulting company specialized in Competitive Intelligence (Paris and Strasbourg, France), providing business advice for several industrial firms.
Nicolas then joined the Business Development department of Transgene (Strasbourg, France), a publicly-traded biopharmaceutical company which develops therapeutic vaccines and immunotherapy products for the treatment of cancers and infectious diseases.
He later became Competitive Intelligence Analyst at Air Liquide (Paris, France), the world leader of industrial and medical gases (>46,000 employees, 75 countries), providing technological watch and strategic support for R&D and marketing operations worldwide.
Since 2007, Nicolas is head of Business Intelligence at Debiopharm Group (Lausanne, Switzerland), an independently-funded biopharmaceutical development company focused on in-licensing, development and out-licensing of small molecules and biologics. He has implemented the Business Intelligence Department (5 people), which helps strategic decision making, identifies key business opportunities, provides operational support and continuously monitors the competitive and business environment.
Nicolas is member of the US and Swiss Societies of Competitive Intelligence Professionals (SCIP, SCIA).
His education includes a MSc in biology, a “Diplôme d’Ingénieur” (Master’s Degree) in applied biochemistry, and a Master’s Degree in Marketing.
Rafaat Rahmani, Lifescience Dynamics
Rafaat Rahmani, President, Lifescience Dynamics
Rafaat founded Lifescience Dynamics in the summer of 2004. Thirteen years on, Lifescience Dynamics is privileged to boast an extraordinary worldwide customer base with teams across the globe supporting firms of all sizes, from top 20 pharmaceutical companies through to smaller niche pharma and biotech firms. Previously, Rafaat was Vice President of a London-based consulting practice where he was responsible for numerous international projects focusing on all aspects of the clinical development and commercialisation environments. He has also previously worked for Eli Lilly & Company, Pepsi-Cola and McDonald’s in marketing and management.
Rafaat was born in India, brought up in Oman/UAE, gained a business degree in the USA and an MBA from Manchester Business School in the UK.
Peter Elsig Raun, GN ReSound A/S (Invited)
Peter Elsig Raun, Senior Director, Market Insights & Analytics, GN ReSound A/S (Invited)
Alfred Reszka, MSD
Alfred Reszka, Executive Director and Head of Global Competitive Intelligence, MSD
Alfred (Al) Reszka is Executive Director and Head of Global Competitive Intelligence at MSD. Al and his team work with clients in Strategy, Marketing, R&D and Manufacturing across a variety of business functions requiring scientific, medical and business intelligence. The group functions as a strategic consultancy within Merck that leverages intelligence to impact strategy and the top and bottom lines. Roles and responsibilities include consulting in product and pipeline intelligence across all therapeutic areas, portfolio prioritization, strategic benchmarking and strategy development, product surveillance and defense, mature product strategies, emerging markets, licensing, business development, M&A and the Merck Library.
Al joined Merck in 1997, and prior to joining the Global Competitive Intelligence group in 2007, he was Senior Research Fellow in Bone Basic Research in R&D, where he led research that elucidated the mechanism of action of alendronate (FOSAMAX) and where he led drug discovery efforts for a variety of osteoporosis programs.
Al earned his Ph.D. in Cell Biology at the University of Illinois, Urbana-Champaign in 1992 and subsequently conducted postdoctoral research on MAP Kinase (ERK1/2) mediated signal transduction with Nobel Laureates, Edmund Fischer and Edwin Krebs at the University of Washington in Seattle.
Heresh Rezavandi, BSc. MSc. Ph.D., UCB Pharma
Heresh Rezavandi, BSc. MSc. Ph.D., Ecosystem Strategic Intelligence Lead, Foresight, Associate Director, UCB Pharma
Heresh is the Global Competitive Intelligence Lead for UCB, a biopharmaceutical company specialising in immunological and CNS disorders. Heresh has a PhD, MSc and BSc in the medical sciences. Heresh was trained by in competitive intelligence when working for consultancies that specialise in this practice. Afterwards, Heresh was invited by UCB to initially set up its R&D CI practice and shortly after led the Global Competitive Intelligence activities as well. Experience includes primary competitive intelligence, competitive intelligence for in-licensing and out-licensing of biopharmaceutical therapies, benchmarking, corporate strategy, analysis of emerging therapies and technologies and market analysis for the pharmaceutical and healthcare industries.
Alex Roland, GSK
Alex Roland, Portfolio Competitor Insights and Analytics Director, GSK
Alex’s background is in benchmarking and competitive intelligence.
Prior to joining GSK, Alex was the Director of R&D Intelligence at MedImmune in Cambridge UK, leading the R&D Intelligence function and providing biologics CI for neuroscience. He also worked for the Thomson Reuters pharmaceutical benchmarking company CMR International. As the Portfolio Manager for CMR’s clinical performance metrics programme, he worked with over thirty pharmaceutical companies, including most of the top-ten.
Alex holds BSc and Ph.D. degrees in biochemistry.
Maritta Sauer, Merck Group
Maritta Sauer, Director Global Business Intelligence, Merck Group
- Key Business Partner for the Business Franchises General Medicine & Endocrinology
- Special focus on business opportunities and market insights in Emerging Markets
- Long-time experience within the healthcare market focusing on Business and Competitive Intelligence
- Previously worked with IMS to build up their consulting services
- Holds a Master of Health Business Administration, Friedrich-Alexander-University Erlangen-Nuernberg
Baljit Singh, INOVIS
Dr. Baljit Singh, Managing Director, INOVIS
A recognized expert in competitive and research intelligence in pharma/ biotechnology and generics, he is known for both his analytical insight and his results-oriented approach. Dr. Singh brings with him nearly a decade of client- and agency-side experience, and will also assume leadership of the new INOVIS offices in India as well as overseeing the day-to-day operations of the pharmaceutical division.
Dr. Singh comes to the company from Novartis Pharma AG, where he most recently served as Global Director of Integrated Insights and helped to develop competitive intelligence (CI) functions and processes which are still in effect today. In addition to leading numerous competitor simulations and strategic scenario planning workshops, Dr. Singh spearheaded Novartis’ most comprehensive generics CI tracking program, earning him, as part of a cross functional team, the highest honors within the global commercial organization.
Previously, Dr. Singh worked as Head of Competitive Intelligence for a major regulatory intelligence firm to help pharmaceutical clients optimize their lifecycle strategies. Dr. Singh studied pharmacy at the Royal Danish School of Pharmacy in Copenhagen, Denmark and received his Ph.D in Pharmaceutics from London School of Pharmacy in 2006. He has also played cricket for the Danish National team for ~10 Years.
Helen Smith, Daiichi Sankyo
Helen Smith, Senior Director, Global Market Research, Daiichi Sankyo
Joanne Taylor, Prescient Healthcare
Dr. Joanne Taylor, VP, Head of Neuroscience, Prescient Healthcare Group
Joanne’s entire career has been in the neuroscience arena – in academia, the pharmaceutical industry and consulting at Prescient, where she is VP, Head of Neuroscience. She is well versed in the particular challenges of drug discovery and development within the neurology space and has witnessed the evolution in the response of the pharma industry to these challenges over a number of years.
After receiving her BSc in pharmacology and PhD in developmental neuroscience from King’s College London, Joanne undertook postdoctoral studies and a junior group leader role in the neurobiology department at the Swiss Federal Institute of Technology (ETH), Zurich, before joining Eisai’s London laboratories on the campus of University College. At Eisai, Joanne led global teams in the discovery of novel therapeutic strategies for neurological conditions, in particular Alzheimer’s disease, multiple sclerosis and Parkinson’s disease. As Director of Strategic Research Planning, Joanne led a review of Eisai’s neuroscience portfolio to identify areas of major focus for internal research, open innovation and strategic alliance, and, as Neuroscience Director responsible for External Research, implemented systematic, scientific evaluation of preclinical- and clinical-stage in-licensing opportunities within the neuroscience focus areas.
At Prescient, Joanne has led a large number of neuroscience projects that have supported assets at various stages in the product life cycle, from new products and established brands through to mature product planning.
Ryan Tohill, Janssen
Ryan Tohill, EMEA Business Insights Manager, Janssen
Ryan has over 10 years of experience in the pharmaceutical and biotech industry, working currently as an EMEA Business Insights lead for Immunology for Janssen, and previously in international roles with Gilead Sciences and Abbott. His experience spans across all BI functions; forecasting, reporting, analytics, market research and competitive intelligence. Ryan has a keen interest in developing the business impact of BI, driving decisions with strong evidence based challenge, ensuring BI is a key strategic partner to the brand team. Alongside his pharma career, Ryan also holds a voluntary position as a Trustee on the Board of Directors for the Cystic Fibrosis Trust based in London.
Uwe-Peter Weitzel, Merck Group
Uwe-Peter Weitzel, Head Scientific Intelligence – Exernal Innovation Biopharma, Merck Group (Invited)
Andrew White, Novartis Pharma AG
Andrew White, Associate Director, Competitive Insights, Novartis Pharma AG
Andrew White is a Competitive Intelligence Manager in the NIBR Knowledge Office at Novartis. He has more than 10 years’ experience supporting early R&D projects in the autoimmunity, transplantation, inflammation and dermatology areas. He has a broad expertise in secondary CI and information management, from novel target validation and patent analysis, to clinical trial monitoring and high level strategic support.
Andrew has recently completed a 6 month job rotation in the New Products group in the Integrated Hospital Care franchise, helping to define the commercial strategy for early clinical phase programs, assist with Business Development & Licensing, and reviewing/updating therapy area strategies, and working with Integrated Insights and Market Access groups.
Prior to joining Novartis, Andrew was a Senior Patent Analyst at Thomson for 4 years, following completion of BSc and Ph.D. degrees in chemistry.